

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Fluazuron / Abamectin Formulation

| | | | |
|----------------|------------------------------|-----------------------------|---|
| Version 9.1 | Revision Date: 14.04.2025 | SDS Number: 803734-00030 | Date of last issue: 24.03.2025 Date of first issue: 12.07.2016 |
|----------------|------------------------------|-----------------------------|---|

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier

Trade name : Fluazuron / Abamectin Formulation

1.2 Relevant identified uses of the substance or mixture and uses advised against

Use of the Substance/Mixture : Veterinary product

Recommended restrictions on use : Not applicable

1.3 Details of the supplier of the safety data sheet

Company : MSD
Drynam Road
K67 P263 Dublin, Ireland

Telephone : +1-908-740-4000

E-mail address of person responsible for the SDS : EHSDATASTEWARD@msd.com

1.4 Emergency telephone number

+1-908-423-6000

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

Classification (REGULATION (EC) No 1272/2008)

| | |
|--|--|
| Flammable liquids, Category 3 | H226: Flammable liquid and vapour. |
| Acute toxicity, Category 4 | H332: Harmful if inhaled. |
| Skin irritation, Category 2 | H315: Causes skin irritation. |
| Eye irritation, Category 2 | H319: Causes serious eye irritation. |
| Skin sensitisation, Category 1 | H317: May cause an allergic skin reaction. |
| Germ cell mutagenicity, Category 2 | H341: Suspected of causing genetic defects. |
| Reproductive toxicity, Category 1B | H360D: May damage the unborn child. |
| Specific target organ toxicity - single exposure, Category 3 | H335: May cause respiratory irritation. |
| Specific target organ toxicity - single exposure, Category 3 | H336: May cause drowsiness or dizziness. |
| Specific target organ toxicity - repeated exposure, Category 2 | H373: May cause damage to organs through prolonged or repeated exposure. |
| Short-term (acute) aquatic hazard, Category 1 | H400: Very toxic to aquatic life. |

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Fluazuron / Abamectin Formulation

Version
9.1

Revision Date:
14.04.2025

SDS Number:
803734-00030

Date of last issue: 24.03.2025
Date of first issue: 12.07.2016

Long-term (chronic) aquatic hazard, Category 1 H410: Very toxic to aquatic life with long lasting effects.

2.2 Label elements

Labelling (REGULATION (EC) No 1272/2008)

Hazard pictograms :



Signal word :

Danger

Hazard statements :

H226 Flammable liquid and vapour.
H315 Causes skin irritation.
H317 May cause an allergic skin reaction.
H319 Causes serious eye irritation.
H332 Harmful if inhaled.
H335 May cause respiratory irritation.
H336 May cause drowsiness or dizziness.
H341 Suspected of causing genetic defects.
H360D May damage the unborn child.
H373 May cause damage to organs through prolonged or repeated exposure.
H410 Very toxic to aquatic life with long lasting effects.

Precautionary statements :

Prevention:

P201 Obtain special instructions before use.
P210 Keep away from heat, hot surfaces, sparks, open flames and other ignition sources. No smoking.
P273 Avoid release to the environment.
P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

Response:

P308 + P313 IF exposed or concerned: Get medical advice/ attention.
P391 Collect spillage.

Hazardous components which must be listed on the label:

Propan-2-ol

N-Methyl-2-pyrrolidone

7-Oxabicyclo[4.1.0]hept-3-ylmethyl 7-oxabicyclo[4.1.0]heptane-3-carboxylate
abamectin (combination of avermectin B1a and avermectin B1b) (ISO)

Additional Labelling

Restricted to professional users.

2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Fluazuron / Abamectin Formulation

Version
9.1

Revision Date:
14.04.2025

SDS Number:
803734-00030

Date of last issue: 24.03.2025
Date of first issue: 12.07.2016

Ecological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Toxicological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Vapours may form explosive mixture with air.

SECTION 3: Composition/information on ingredients

3.2 Mixtures

Components

| Chemical name | CAS-No. EC-No. Index-No. Registration number | Classification | Concentration (% w/w) |
|---|---|--|--------------------------|
| Propan-2-ol | 67-63-0 200-661-7 603-117-00-0 | Flam. Liq. 2; H225 Eye Irrit. 2; H319 STOT SE 3; H336 | >= 30 - < 50 |
| N-Methyl-2-pyrrolidone | 872-50-4 212-828-1 606-021-00-7 | Skin Irrit. 2; H315 Eye Irrit. 2; H319 Repr. 1B; H360D STOT SE 3; H335 specific concentration limit STOT SE 3; H335 >= 10 % | >= 30 - < 50 |
| Fluazuron | 86811-58-7 | Aquatic Acute 1; H400 Aquatic Chronic 1; H410 M-Factor (Acute aquatic toxicity): 1,000 M-Factor (Chronic aquatic toxicity): 1,000 | >= 2.5 - < 10 |
| abamectin (combination of avermectin B1a and avermectin B1b) (ISO) | 71751-41-2 606-143-00-0 | Acute Tox. 2; H300 Acute Tox. 1; H330 Acute Tox. 3; H311 Repr. 2; H361fd STOT RE 1; H372 (Central nervous system) | >= 1 - < 2.5 |

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Fluazuron / Abamectin Formulation

Version
9.1

Revision Date:
14.04.2025

SDS Number:
803734-00030

Date of last issue: 24.03.2025
Date of first issue: 12.07.2016

| | | | |
|---|--|--|-----------------|
| | | Aquatic Acute 1; H400 Aquatic Chronic 1; H410 M-Factor (Acute aquatic toxicity): 10,000 M-Factor (Chronic aquatic toxicity): 10,000 specific concentration limit STOT RE 1; H372 >= 5 % STOT RE 2; H373 0.5 - < 5 % | |
| 7-Oxabicyclo[4.1.0]hept-3-ylmethyl 7-oxabicyclo[4.1.0]heptane-3-carboxylate | 2386-87-0 219-207-4 607-773-00-9 | Skin Sens. 1; H317 Muta. 2; H341 STOT RE 2; H373 (nasal cavity) Aquatic Chronic 3; H412 | >= 1 - < 2.5 |
| 2,6-Di-tert-butyl-p-cresol | 128-37-0 204-881-4 | Aquatic Acute 1; H400 Aquatic Chronic 1; H410 M-Factor (Acute aquatic toxicity): 1 M-Factor (Chronic aquatic toxicity): 1 | >= 0.1 - < 0.25 |

For explanation of abbreviations see section 16.

SECTION 4: First aid measures

4.1 Description of first aid measures

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.

When symptoms persist or in all cases of doubt seek medical advice.

Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

If inhaled : If inhaled, remove to fresh air.

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Fluazuron / Abamectin Formulation

Version
9.1

Revision Date:
14.04.2025

SDS Number:
803734-00030

Date of last issue: 24.03.2025
Date of first issue: 12.07.2016

If not breathing, give artificial respiration.
If breathing is difficult, give oxygen.
Get medical attention.

In case of skin contact

: In case of contact, immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Get medical attention.
Wash clothing before reuse.
Thoroughly clean shoes before reuse.

In case of eye contact

: In case of contact, immediately flush eyes with plenty of water for at least 15 minutes.
If easy to do, remove contact lens, if worn.
Get medical attention.

If swallowed

: If swallowed, DO NOT induce vomiting.
Get medical attention.
Rinse mouth thoroughly with water.
Never give anything by mouth to an unconscious person.

4.2 Most important symptoms and effects, both acute and delayed

Risks

: Causes skin irritation.
May cause an allergic skin reaction.
Causes serious eye irritation.
Harmful if inhaled.
May cause respiratory irritation.
May cause drowsiness or dizziness.
Suspected of causing genetic defects.
May damage the unborn child.
May cause damage to organs through prolonged or repeated exposure.

4.3 Indication of any immediate medical attention and special treatment needed

Treatment

: Treat symptomatically and supportively.

SECTION 5: Firefighting measures

5.1 Extinguishing media

Suitable extinguishing media : Water spray
Alcohol-resistant foam
Carbon dioxide (CO₂)
Dry chemical

Unsuitable extinguishing media : High volume water jet

5.2 Special hazards arising from the substance or mixture

Specific hazards during fire- : Do not use a solid water stream as it may scatter and spread

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Fluazuron / Abamectin Formulation

| | | | |
|----------------|------------------------------|-----------------------------|---|
| Version 9.1 | Revision Date: 14.04.2025 | SDS Number: 803734-00030 | Date of last issue: 24.03.2025 Date of first issue: 12.07.2016 |
|----------------|------------------------------|-----------------------------|---|

fighting fire.
Flash back possible over considerable distance.
Vapours may form explosive mixtures with air.
Exposure to combustion products may be a hazard to health.

Hazardous combustion products : Carbon oxides
Nitrogen oxides (NOx)
Chlorine compounds
Fluorine compounds

5.3 Advice for firefighters

Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus.
Use personal protective equipment.

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions : Remove all sources of ignition.
Use personal protective equipment.
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

6.2 Environmental precautions

Environmental precautions : Avoid release to the environment.
Prevent further leakage or spillage if safe to do so.
Prevent spreading over a wide area (e.g. by containment or oil barriers).
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.

6.3 Methods and material for containment and cleaning up

Methods for cleaning up : Non-sparking tools should be used.
Soak up with inert absorbent material.
Suppress (knock down) gases/vapours/mists with a water spray jet.
For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container.
Clean up remaining materials from spill with suitable absorbent.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Fluazuron / Abamectin Formulation

| | | | |
|----------------|------------------------------|-----------------------------|---|
| Version 9.1 | Revision Date: 14.04.2025 | SDS Number: 803734-00030 | Date of last issue: 24.03.2025 Date of first issue: 12.07.2016 |
|----------------|------------------------------|-----------------------------|---|

employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage

7.1 Precautions for safe handling

| | |
|-------------------------|---|
| Technical measures | : See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section. |
| Local/Total ventilation | : If sufficient ventilation is unavailable, use with local exhaust ventilation. Use explosion-proof electrical, ventilating and lighting equipment. |
| Advice on safe handling | : Do not get on skin or clothing. Do not breathe mist or vapours. Do not swallow. Do not get in eyes. Wash skin thoroughly after handling. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment Non-sparking tools should be used. Keep container tightly closed. Already sensitised individuals, and those susceptible to asthma, allergies, chronic or recurrent respiratory disease, should consult their physician regarding working with respiratory irritants or sensitisers. Keep away from heat, hot surfaces, sparks, open flames and other ignition sources. No smoking. Take precautionary measures against static discharges. Do not eat, drink or smoke when using this product. Take care to prevent spills, waste and minimize release to the environment. |
| Hygiene measures | : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Contaminated work clothing should not be allowed out of the workplace. Wash contaminated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls. |

7.2 Conditions for safe storage, including any incompatibilities

| | |
|---|---|
| Requirements for storage areas and containers | : Keep in properly labelled containers. Store locked up. Keep tightly closed. Keep in a cool, well-ventilated place. Store in accordance with the particular national regulations. Keep |
|---|---|

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Fluazuron / Abamectin Formulation

Version
9.1

Revision Date:
14.04.2025

SDS Number:
803734-00030

Date of last issue: 24.03.2025
Date of first issue: 12.07.2016

away from heat and sources of ignition.

Advice on common storage : Do not store with the following product types:
Strong oxidizing agents
Self-reactive substances and mixtures
Organic peroxides
Flammable solids
Pyrophoric liquids
Pyrophoric solids
Self-heating substances and mixtures
Substances and mixtures, which in contact with water, emit flammable gases
Explosives
Gases
Very acutely toxic substances and mixtures

7.3 Specific end use(s)

Specific use(s) : No data available

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

Occupational Exposure Limits

| Components | CAS-No. | Value type (Form of exposure) | Control parameters | Basis |
|------------------------|---|-------------------------------|--------------------------------|-------------|
| Propan-2-ol | 67-63-0 | OELV - 8 hrs (TWA) | 200 ppm | IE OEL |
| | Further information: Substances which have the capacity to penetrate intact skin when they come in contact with it, and be absorbed into the body | | | |
| | | OELV - 15 min (STEL) | 400 ppm | IE OEL |
| | Further information: Substances which have the capacity to penetrate intact skin when they come in contact with it, and be absorbed into the body | | | |
| N-Methyl-2-pyrrolidone | 872-50-4 | TWA | 10 ppm 40 mg/m ³ | 2009/161/EU |
| | Further information: Identifies the possibility of significant uptake through the skin, Indicative | | | |
| | | STEL | 20 ppm 80 mg/m ³ | 2009/161/EU |
| | Further information: Identifies the possibility of significant uptake through the skin, Indicative | | | |
| | | TWA | 10 ppm 40 mg/m ³ | 2004/37/EC |
| | Further information: Skin, Carcinogens or mutagens | | | |
| | | STEL | 20 ppm 80 mg/m ³ | 2004/37/EC |
| | Further information: Skin, Carcinogens or mutagens | | | |
| | | OELV - 8 hrs (TWA) | 10 ppm 40 mg/m ³ | IE OEL |

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Fluazuron / Abamectin Formulation

Version
9.1

Revision Date:
14.04.2025

SDS Number:
803734-00030

Date of last issue: 24.03.2025
Date of first issue: 12.07.2016

| | | | | |
|--|---|----------------------|--------------------------------|----------|
| | Further information: Substances which have the capacity to penetrate intact skin when they come in contact with it, and be absorbed into the body | | | |
| | | OELV - 15 min (STEL) | 20 ppm 80 mg/m ³ | IE OEL |
| | Further information: Substances which have the capacity to penetrate intact skin when they come in contact with it, and be absorbed into the body | | | |
| Fluazuron | 86811-58-7 | TWA | 60 µg/m ³ (OEB 3) | Internal |
| | | Wipe limit | 600 µg/ 100cm ² | Internal |
| abamectin (combination of avermectin B1a and avermectin B1b) (ISO) | 71751-41-2 | TWA | 15 µg/m ³ (OEB 3) | Internal |
| | | Wipe limit | 150 µg/100 cm ² | Internal |
| 2,6-Di-tert-butyl-p-cresol | 128-37-0 | OELV - 8 hrs (TWA) | 2 mg/m ³ | IE OEL |

Derived No Effect Level (DNEL) according to Regulation (EC) No. 1907/2006

| Substance name | End Use | Exposure routes | Potential health effects | Value |
|---|-----------|-----------------|----------------------------|------------------------|
| N-Methyl-2-pyrrolidone | Workers | Inhalation | Long-term systemic effects | 14.4 mg/m ³ |
| | Workers | Inhalation | Long-term local effects | 40 mg/m ³ |
| | Workers | Skin contact | Long-term systemic effects | 4.8 mg/kg bw/day |
| | Consumers | Inhalation | Long-term systemic effects | 3.6 mg/m ³ |
| | Consumers | Inhalation | Long-term local effects | 4.5 mg/m ³ |
| | Consumers | Skin contact | Long-term systemic effects | 2.4 mg/kg bw/day |
| | Consumers | Ingestion | Long-term systemic effects | 0.85 mg/kg bw/day |
| 7-Oxabicyclo[4.1.0]hept-3-ylmethyl 7-oxabicyclo[4.1.0]heptane-3-carboxylate | Workers | Inhalation | Long-term systemic effects | 0.18 mg/m ³ |
| | Workers | Inhalation | Long-term local effects | 0.18 mg/m ³ |
| | Workers | Skin contact | Long-term systemic effects | 0.05 mg/kg bw/day |
| Propan-2-ol | Workers | Inhalation | Long-term systemic effects | 500 mg/m ³ |
| | Workers | Skin contact | Long-term systemic effects | 888 mg/kg bw/day |
| | Consumers | Inhalation | Long-term systemic effects | 89 mg/m ³ |
| | Consumers | Skin contact | Long-term systemic | 319 mg/kg |

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Fluazuron / Abamectin Formulation

Version
9.1

Revision Date:
14.04.2025

SDS Number:
803734-00030

Date of last issue: 24.03.2025
Date of first issue: 12.07.2016

| | | | effects | bw/day |
|----------------------------|-----------|------------|----------------------------|-------------------|
| | Consumers | Ingestion | Long-term systemic effects | 26 mg/kg bw/day |
| 2,6-Di-tert-butyl-p-cresol | Workers | Inhalation | Long-term systemic effects | 3.5 mg/m3 |
| | Workers | Dermal | Long-term systemic effects | 0.5 mg/kg bw/day |
| | Consumers | Inhalation | Long-term systemic effects | 0.86 mg/m3 |
| | Consumers | Dermal | Long-term systemic effects | 0.25 mg/kg bw/day |
| | Consumers | Ingestion | Long-term systemic effects | 0.25 mg/kg bw/day |

Predicted No Effect Concentration (PNEC) according to Regulation (EC) No. 1907/2006

| Substance name | Environmental Compartment | Value |
|---|----------------------------|--------------------------------|
| N-Methyl-2-pyrrolidone | Fresh water | 0.25 mg/l |
| | Freshwater - intermittent | 5 mg/l |
| | Marine water | 0.025 mg/l |
| | Sewage treatment plant | 10 mg/l |
| | Fresh water sediment | 1.09 mg/kg dry weight (d.w.) |
| | Marine sediment | 0.109 mg/kg dry weight (d.w.) |
| | Soil | 0.07 mg/kg dry weight (d.w.) |
| 7-Oxabicyclo[4.1.0]hept-3-ylmethyl 7-oxabicyclo[4.1.0]heptane-3-carboxylate | Fresh water | 0.024 mg/l |
| | Freshwater - intermittent | 0.24 mg/l |
| | Marine water | 0.0024 mg/l |
| | Sewage treatment plant | 19.5 mg/l |
| | Fresh water sediment | 0.211 mg/kg dry weight (d.w.) |
| | Marine sediment | 0.0211 mg/kg dry weight (d.w.) |
| | Soil | 0.0282 mg/kg dry weight (d.w.) |
| Propan-2-ol | Fresh water | 140.9 mg/l |
| | Marine water | 140.9 mg/l |
| | Intermittent use/release | 140.9 mg/l |
| | Sewage treatment plant | 2251 mg/l |
| | Fresh water sediment | 552 mg/kg dry weight (d.w.) |
| | Marine sediment | 552 mg/kg dry weight (d.w.) |
| | Soil | 28 mg/kg dry weight (d.w.) |
| | Oral (Secondary Poisoning) | 160 mg/kg food |
| 2,6-Di-tert-butyl-p-cresol | Fresh water | 0.199 µg/l |
| | Intermittent use/release | 0.02 µg/l |

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Fluazuron / Abamectin Formulation

Version 9.1 Revision Date: 14.04.2025 SDS Number: 803734-00030 Date of last issue: 24.03.2025 Date of first issue: 12.07.2016

| | | |
|--|----------------------------|---------------------------------|
| | Marine water | 0.02 µg/l |
| | Sewage treatment plant | 0.17 mg/l |
| | Fresh water sediment | 0.0996 mg/kg dry weight (d.w.) |
| | Marine sediment | 0.00996 mg/kg dry weight (d.w.) |
| | Soil | 0.04769 mg/kg dry weight (d.w.) |
| | Oral (Secondary Poisoning) | 8.33 mg/kg food |

8.2 Exposure controls

Engineering measures

Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip-less quick connections).

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).

Minimize open handling.

Use explosion-proof electrical, ventilating and lighting equipment.

Personal protective equipment

Eye/face protection : Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Hand protection

Material : Chemical-resistant gloves

Remarks : Consider double gloving. Take note that the product is flammable, which may impact the selection of hand protection.

Skin and body protection

: Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces.

Use appropriate degowning techniques to remove potentially contaminated clothing.

Respiratory protection

: If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection. Filter should conform to I.S. EN 14387

Filter type : Combined particulates and organic vapour type (A-P)

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

Physical state : liquid

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Fluazuron / Abamectin Formulation

| | | | |
|----------------|------------------------------|-----------------------------|---|
| Version 9.1 | Revision Date: 14.04.2025 | SDS Number: 803734-00030 | Date of last issue: 24.03.2025 Date of first issue: 12.07.2016 |
|----------------|------------------------------|-----------------------------|---|

| | | |
|--|---|-------------------|
| Colour | : | No data available |
| Odour | : | No data available |
| Odour Threshold | : | No data available |
| Melting point/freezing point | : | No data available |
| Initial boiling point and boiling range | : | No data available |
| Flammability (solid, gas) | : | Not applicable |
| Flammability (liquids) | : | Not applicable |
| Upper explosion limit / Upper flammability limit | : | No data available |
| Lower explosion limit / Lower flammability limit | : | No data available |
| Flash point | : | 28 °C |
| Auto-ignition temperature | : | No data available |
| Decomposition temperature | : | No data available |
| pH | : | No data available |
| Viscosity | | |
| Viscosity, kinematic | : | No data available |
| Solubility(ies) | | |
| Water solubility | : | No data available |
| Partition coefficient: n-octanol/water | : | Not applicable |
| Vapour pressure | : | No data available |
| Relative density | : | No data available |
| Density | : | No data available |
| Relative vapour density | : | No data available |
| Particle characteristics | | |
| Particle size | : | Not applicable |

9.2 Other information

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Fluazuron / Abamectin Formulation

| | | | |
|----------------|------------------------------|-----------------------------|---|
| Version 9.1 | Revision Date: 14.04.2025 | SDS Number: 803734-00030 | Date of last issue: 24.03.2025 Date of first issue: 12.07.2016 |
|----------------|------------------------------|-----------------------------|---|

| | | |
|----------------------|---|--|
| Explosives | : | Not explosive |
| Oxidizing properties | : | The substance or mixture is not classified as oxidizing. |
| Evaporation rate | : | No data available |
| Molecular weight | : | No data available |

SECTION 10: Stability and reactivity

10.1 Reactivity

Not classified as a reactivity hazard.

10.2 Chemical stability

Stable under normal conditions.

10.3 Possibility of hazardous reactions

| | | |
|---------------------|---|---|
| Hazardous reactions | : | Flammable liquid and vapour. Vapours may form explosive mixture with air. Can react with strong oxidizing agents. |
|---------------------|---|---|

10.4 Conditions to avoid

| | | |
|---------------------|---|--------------------------|
| Conditions to avoid | : | Heat, flames and sparks. |
|---------------------|---|--------------------------|

10.5 Incompatible materials

| | | |
|--------------------|---|------------------|
| Materials to avoid | : | Oxidizing agents |
|--------------------|---|------------------|

10.6 Hazardous decomposition products

No hazardous decomposition products are known.

SECTION 11: Toxicological information

11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008

| | | |
|--|---|--|
| Information on likely routes of exposure | : | Inhalation Skin contact Ingestion Eye contact |
|--|---|--|

Acute toxicity

Harmful if inhaled.

Product:

| | | |
|---------------------------|---|--|
| Acute oral toxicity | : | Acute toxicity estimate: > 2,000 mg/kg Method: Calculation method |
| Acute inhalation toxicity | : | Acute toxicity estimate: 2.06 mg/l Exposure time: 4 h Test atmosphere: dust/mist Method: Calculation method |

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Fluazuron / Abamectin Formulation

| | | | |
|----------------|------------------------------|-----------------------------|---|
| Version 9.1 | Revision Date: 14.04.2025 | SDS Number: 803734-00030 | Date of last issue: 24.03.2025 Date of first issue: 12.07.2016 |
|----------------|------------------------------|-----------------------------|---|

Acute dermal toxicity : Acute toxicity estimate: > 2,000 mg/kg
Method: Calculation method

Components:

Propan-2-ol:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg
Acute inhalation toxicity : LC50 (Rat): > 25 mg/l
Exposure time: 6 h
Test atmosphere: vapour
Acute dermal toxicity : LD50 (Rabbit): > 5,000 mg/kg

N-Methyl-2-pyrrolidone:

Acute oral toxicity : LD50 (Rat): 4,150 mg/kg
Method: OECD Test Guideline 401
Remarks: The test was conducted equivalent or similar to guideline
Acute inhalation toxicity : LC50 (Rat): > 5.1 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist
Method: OECD Test Guideline 403
Remarks: The test was conducted according to guideline
Acute dermal toxicity : LD50 (Rat): > 5,000 mg/kg
Method: OECD Test Guideline 402
Remarks: The test was conducted equivalent or similar to guideline

Fluazuron:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg
Method: OECD Test Guideline 401
Acute inhalation toxicity : LC50 (Rat): > 6.0 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist
Method: OECD Test Guideline 403
Acute dermal toxicity : LD50 (Rat): > 2,000 mg/kg
Method: OECD Test Guideline 402

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Acute oral toxicity : LD50 (Rat): 24 mg/kg
LD50 (Mouse): 10 mg/kg
LDLo (Monkey): 24 mg/kg
Symptoms: Dilatation of the pupil

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Fluazuron / Abamectin Formulation

Version
9.1

Revision Date:
14.04.2025

SDS Number:
803734-00030

Date of last issue: 24.03.2025
Date of first issue: 12.07.2016

Acute inhalation toxicity : LC50 (Rat): 0.023 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist

Acute dermal toxicity : LD50 (Rat): 330 mg/kg
LD50 (Rabbit): 2,000 mg/kg

7-Oxabicyclo[4.1.0]hept-3-ylmethyl 7-oxabicyclo[4.1.0]heptane-3-carboxylate:

Acute oral toxicity : LD50 (Rat, male): > 2,959 - 5,000 mg/kg
Method: OECD Test Guideline 401

Acute inhalation toxicity : LC50 (Rat): >= 5.19 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist
Method: OECD Test Guideline 436
Assessment: The substance or mixture has no acute inhalation toxicity

Acute dermal toxicity : LD50 (Rat): > 2,000 mg/kg
Method: OECD Test Guideline 402
Assessment: The substance or mixture has no acute dermal toxicity

2,6-Di-tert-butyl-p-cresol:

Acute oral toxicity : LD50 (Rat): > 6,000 mg/kg
Method: OECD Test Guideline 401

Acute dermal toxicity : LD50 (Rat): > 2,000 mg/kg
Method: OECD Test Guideline 402
Assessment: The substance or mixture has no acute dermal toxicity

Skin corrosion/irritation

Causes skin irritation.

Components:

Propan-2-ol:

Species : Rabbit
Result : No skin irritation

N-Methyl-2-pyrrolidone:

Species : Rabbit
Method : OECD Test Guideline 404
Result : Skin irritation
Remarks : The test was conducted equivalent or similar to guideline

Fluazuron:

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Fluazuron / Abamectin Formulation

| | | | |
|----------------|------------------------------|-----------------------------|---|
| Version 9.1 | Revision Date: 14.04.2025 | SDS Number: 803734-00030 | Date of last issue: 24.03.2025 Date of first issue: 12.07.2016 |
|----------------|------------------------------|-----------------------------|---|

| | | |
|---------|---|-------------------------|
| Species | : | Rabbit |
| Method | : | OECD Test Guideline 404 |
| Result | : | No skin irritation |

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

| | | |
|---------|---|--------------------|
| Species | : | Rabbit |
| Result | : | No skin irritation |

7-Oxabicyclo[4.1.0]hept-3-ylmethyl 7-oxabicyclo[4.1.0]heptane-3-carboxylate:

| | | |
|---------|---|-------------------------|
| Species | : | Rabbit |
| Method | : | OECD Test Guideline 404 |
| Result | : | No skin irritation |

2,6-Di-tert-butyl-p-cresol:

| | | |
|---------|---|--------------------------------------|
| Species | : | Rabbit |
| Method | : | OECD Test Guideline 404 |
| Result | : | No skin irritation |
| Remarks | : | Based on data from similar materials |

Serious eye damage/eye irritation

Causes serious eye irritation.

Components:

Propan-2-ol:

| | | |
|---------|---|--|
| Species | : | Rabbit |
| Result | : | Irritation to eyes, reversing within 21 days |

N-Methyl-2-pyrrolidone:

| | | |
|---------|---|---|
| Species | : | Rabbit |
| Method | : | OECD Test Guideline 405 |
| Result | : | Irritation to eyes, reversing within 21 days |
| Remarks | : | The test was conducted equivalent or similar to guideline |

Fluazuron:

| | | |
|---------|---|-------------------------|
| Species | : | Rabbit |
| Method | : | OECD Test Guideline 405 |
| Result | : | Mild eye irritation |

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

| | | |
|---------|---|---------------------|
| Species | : | Rabbit |
| Result | : | Mild eye irritation |

7-Oxabicyclo[4.1.0]hept-3-ylmethyl 7-oxabicyclo[4.1.0]heptane-3-carboxylate:

| | | |
|---------|---|-------------------------|
| Species | : | Rabbit |
| Method | : | OECD Test Guideline 405 |
| Result | : | No eye irritation |

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Fluazuron / Abamectin Formulation

Version
9.1

Revision Date:
14.04.2025

SDS Number:
803734-00030

Date of last issue: 24.03.2025
Date of first issue: 12.07.2016

2,6-Di-tert-butyl-p-cresol:

Species : Rabbit
Method : OECD Test Guideline 405
Result : No eye irritation
Remarks : Based on data from similar materials

Respiratory or skin sensitisation

Skin sensitisation

May cause an allergic skin reaction.

Respiratory sensitisation

Not classified based on available information.

Components:

Propan-2-ol:

Test Type : Buehler Test
Exposure routes : Skin contact
Species : Guinea pig
Method : OECD Test Guideline 406
Result : negative

N-Methyl-2-pyrrolidone:

Test Type : Local lymph node assay (LLNA)
Exposure routes : Skin contact
Species : Mouse
Method : OECD Test Guideline 429
Result : negative
Remarks : Based on data from similar materials

Fluazuron:

Exposure routes : Skin contact
Species : Guinea pig
Result : negative

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Test Type : Maximisation Test
Exposure routes : Skin contact
Result : Not a skin sensitizer.

7-Oxabicyclo[4.1.0]hept-3-ylmethyl 7-oxabicyclo[4.1.0]heptane-3-carboxylate:

Test Type : Maximisation Test
Exposure routes : Skin contact
Species : Guinea pig
Result : positive

Assessment : Probability or evidence of skin sensitisation in humans

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Fluazuron / Abamectin Formulation

Version
9.1

Revision Date:
14.04.2025

SDS Number:
803734-00030

Date of last issue: 24.03.2025
Date of first issue: 12.07.2016

2,6-Di-tert-butyl-p-cresol:

Test Type : Human repeat insult patch test (HRIPT)
Exposure routes : Skin contact
Species : Humans
Result : negative

Germ cell mutagenicity

Suspected of causing genetic defects.

Components:

Propan-2-ol:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: In vitro mammalian cell gene mutation test
Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
Species: Mouse
Application Route: Intraperitoneal injection
Result: negative

N-Methyl-2-pyrrolidone:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Method: OECD Test Guideline 471
Result: negative
Remarks: The test was conducted according to guideline

Test Type: In vitro mammalian cell gene mutation test
Method: OECD Test Guideline 476
Result: negative
Remarks: The test was conducted according to guideline

Test Type: DNA damage and repair, unscheduled DNA synthesis in mammalian cells (in vitro)
Method: OECD Test Guideline 482
Result: negative
Remarks: The test was conducted equivalent or similar to guideline

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
Species: Mouse
Application Route: Ingestion
Method: OECD Test Guideline 474
Result: negative
Remarks: The test was conducted according to guideline

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Fluazuron / Abamectin Formulation

| | | | |
|----------------|------------------------------|-----------------------------|---|
| Version 9.1 | Revision Date: 14.04.2025 | SDS Number: 803734-00030 | Date of last issue: 24.03.2025 Date of first issue: 12.07.2016 |
|----------------|------------------------------|-----------------------------|---|

Fluazuron:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: DNA Repair
Result: negative

Test Type: In vitro mammalian cell gene mutation test
Result: negative

Genotoxicity in vivo : Test Type: Cytogenetic assay
Species: Hamster
Result: equivocal

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: In vitro mammalian cell gene mutation test
Test system: Chinese hamster lung cells
Result: negative

Test Type: Alkaline elution assay
Result: negative

Genotoxicity in vivo : Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis)
Species: Mouse
Application Route: Intraperitoneal injection
Result: negative

7-Oxabicyclo[4.1.0]hept-3-ylmethyl 7-oxabicyclo[4.1.0]heptane-3-carboxylate:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Method: OECD Test Guideline 471
Result: positive

Test Type: In vitro mammalian cell gene mutation test
Result: positive

Test Type: In vitro sister chromatid exchange assay in mammalian cells
Result: positive

Test Type: DNA damage and repair, unscheduled DNA synthesis in mammalian cells (in vitro)
Result: positive

Genotoxicity in vivo : Test Type: Unscheduled DNA synthesis (UDS) test with mammalian liver cells in vivo
Species: Rat
Application Route: Ingestion

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Fluazuron / Abamectin Formulation

Version
9.1

Revision Date:
14.04.2025

SDS Number:
803734-00030

Date of last issue: 24.03.2025
Date of first issue: 12.07.2016

Method: OECD Test Guideline 486
Result: negative

Test Type: Micronucleus test
Species: Mouse
Application Route: Intraperitoneal injection
Result: negative

Test Type: Transgenic rodent somatic cell gene mutation assay
Species: Mouse
Application Route: Ingestion
Method: OECD Test Guideline 488
Result: positive

Germ cell mutagenicity- Assessment : Positive result(s) from in vivo mammalian somatic cell mutagenicity tests.

2,6-Di-tert-butyl-p-cresol:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: In vitro mammalian cell gene mutation test
Result: negative

Test Type: Chromosome aberration test in vitro
Result: negative

Genotoxicity in vivo : Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis)
Species: Rat
Application Route: Ingestion
Result: negative

Carcinogenicity

Not classified based on available information.

Components:

Propan-2-ol:

Species : Rat
Application Route : inhalation (vapour)
Exposure time : 104 weeks
Method : OECD Test Guideline 451
Result : negative

N-Methyl-2-pyrrolidone:

Species : Rat
Application Route : Ingestion
Exposure time : 2 Years
Method : OECD Test Guideline 451

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Fluazuron / Abamectin Formulation

| | | | |
|----------------|------------------------------|-----------------------------|---|
| Version 9.1 | Revision Date: 14.04.2025 | SDS Number: 803734-00030 | Date of last issue: 24.03.2025 Date of first issue: 12.07.2016 |
|----------------|------------------------------|-----------------------------|---|

| | | |
|-------------------|---|---|
| Result | : | negative |
| Remarks | : | The test was conducted according to guideline |
| Species | : | Rat |
| Application Route | : | Inhalation |
| Exposure time | : | 2 Years |
| Method | : | OECD Test Guideline 453 |
| Result | : | negative |
| Remarks | : | The test was conducted equivalent or similar to guideline |

Fluazuron:

| | | |
|-------------------|---|-------------------------|
| Species | : | Rat |
| Application Route | : | Ingestion |
| Exposure time | : | 2 Years |
| Method | : | OECD Test Guideline 453 |
| Result | : | negative |
| Species | : | Mouse |
| Application Route | : | Ingestion |
| Exposure time | : | 2 Years |
| Result | : | negative |

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

| | | |
|-------------------|---|-----------|
| Species | : | Rat |
| Application Route | : | Oral |
| Exposure time | : | 105 weeks |
| Result | : | negative |
| Species | : | Mouse |
| Application Route | : | Oral |
| Exposure time | : | 93 weeks |
| Result | : | negative |

7-Oxabicyclo[4.1.0]hept-3-ylmethyl 7-oxabicyclo[4.1.0]heptane-3-carboxylate:

| | | |
|-------------------|---|--------------|
| Species | : | Mouse |
| Application Route | : | Skin contact |
| Exposure time | : | 29 Months |
| Result | : | negative |

2,6-Di-tert-butyl-p-cresol:

| | | |
|-------------------|---|-----------|
| Species | : | Rat |
| Application Route | : | Ingestion |
| Exposure time | : | 22 Months |
| Result | : | negative |

Reproductive toxicity

May damage the unborn child.

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Fluazuron / Abamectin Formulation

Version
9.1

Revision Date:
14.04.2025

SDS Number:
803734-00030

Date of last issue: 24.03.2025
Date of first issue: 12.07.2016

Components:

Propan-2-ol:

Effects on fertility

: Test Type: Two-generation reproduction toxicity study
Species: Rat
Application Route: Ingestion
Result: negative

Effects on foetal development

: Test Type: Embryo-foetal development
Species: Rat
Application Route: Ingestion
Result: negative

N-Methyl-2-pyrrolidone:

Effects on fertility

: Test Type: Two-generation reproduction toxicity study
Species: Rat
Application Route: Ingestion
Method: OECD Test Guideline 416
Result: negative
Remarks: The test was conducted according to guideline

Effects on foetal development

: Test Type: Embryo-foetal development
Species: Rat
Application Route: Ingestion
Method: OECD Test Guideline 414
Result: positive
Remarks: The test was conducted according to guideline

Test Type: Fertility/early embryonic development
Species: Rat
Application Route: inhalation (vapour)
Method: OECD Test Guideline 414
Result: positive
Remarks: The test was conducted equivalent or similar to guideline

Test Type: Embryo-foetal development
Species: Rabbit
Application Route: Ingestion
Method: OECD Test Guideline 414
Result: positive
Remarks: The test was conducted equivalent or similar to guideline

Reproductive toxicity - Assessment

: Clear evidence of adverse effects on development, based on animal experiments.

Fluazuron:

Effects on fertility

: Test Type: Two-generation reproduction toxicity study
Species: Rat
Application Route: Ingestion
Result: negative

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Fluazuron / Abamectin Formulation

Version
9.1

Revision Date:
14.04.2025

SDS Number:
803734-00030

Date of last issue: 24.03.2025
Date of first issue: 12.07.2016

Effects on foetal development

: Test Type: Embryo-foetal development
Species: Rat
Application Route: Ingestion
Result: negative

Test Type: Embryo-foetal development
Species: Rabbit
Application Route: Ingestion
Method: OECD Test Guideline 414
Result: negative

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Effects on fertility

: Test Type: Fertility
Species: Rat, male
Application Route: Oral
Result: Effects on fertility

Test Type: Two-generation reproduction toxicity study
Species: Rat
Application Route: Oral
Early Embryonic Development: NOAEL: 0.12 mg/kg body weight
Result: Fetotoxicity

Effects on foetal development

: Test Type: Embryo-foetal development
Species: Mouse
Application Route: Oral
General Toxicity Maternal: NOAEL: 0.05 mg/kg body weight
Developmental Toxicity: NOAEL: 0.2 mg/kg body weight
Result: Cleft palate
Remarks: Adverse developmental effects were observed

Test Type: Embryo-foetal development
Species: Rabbit
Application Route: Oral
Developmental Toxicity: LOAEL: 2 mg/kg body weight
Result: Cleft palate, Teratogenic effects, Reduced embryonic survival
Remarks: Adverse developmental effects were observed

Test Type: Development
Species: Rat
Application Route: Oral
Developmental Toxicity: LOAEL: 1.6 mg/kg body weight
Result: Teratogenic effects

Reproductive toxicity - Assessment

: Some evidence of adverse effects on sexual function and fertility, based on animal experiments., Some evidence of adverse effects on development, based on animal experiments.

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Fluazuron / Abamectin Formulation

Version
9.1

Revision Date:
14.04.2025

SDS Number:
803734-00030

Date of last issue: 24.03.2025
Date of first issue: 12.07.2016

7-Oxabicyclo[4.1.0]hept-3-ylmethyl 7-oxabicyclo[4.1.0]heptane-3-carboxylate:

Effects on foetal development : Test Type: Embryo-foetal development
Species: Rat
Application Route: Ingestion
Method: OECD Test Guideline 414
Result: negative

2,6-Di-tert-butyl-p-cresol:

Effects on fertility : Test Type: Two-generation reproduction toxicity study
Species: Rat
Application Route: Ingestion
Result: negative

Effects on foetal development : Test Type: Embryo-foetal development
Species: Rat
Application Route: Ingestion
Result: negative

STOT - single exposure

May cause respiratory irritation.
May cause drowsiness or dizziness.

Components:

Propan-2-ol:

Assessment : May cause drowsiness or dizziness.

N-Methyl-2-pyrrolidone:

Assessment : May cause respiratory irritation.

STOT - repeated exposure

May cause damage to organs through prolonged or repeated exposure.

Components:

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Exposure routes : Ingestion
Target Organs : Central nervous system
Assessment : Causes damage to organs through prolonged or repeated exposure.

7-Oxabicyclo[4.1.0]hept-3-ylmethyl 7-oxabicyclo[4.1.0]heptane-3-carboxylate:

Exposure routes : Ingestion
Target Organs : nasal cavity
Assessment : Shown to produce significant health effects in animals at concentrations of >10 to 100 mg/kg bw.

2,6-Di-tert-butyl-p-cresol:

Assessment : No significant health effects observed in animals at concentra-

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Fluazuron / Abamectin Formulation

| | | | |
|----------------|------------------------------|-----------------------------|---|
| Version 9.1 | Revision Date: 14.04.2025 | SDS Number: 803734-00030 | Date of last issue: 24.03.2025 Date of first issue: 12.07.2016 |
|----------------|------------------------------|-----------------------------|---|

tions of 100 mg/kg bw or less.

Repeated dose toxicity

Components:

Propan-2-ol:

| | | |
|-------------------|---|---------------------|
| Species | : | Rat |
| NOAEL | : | 12.5 mg/l |
| Application Route | : | inhalation (vapour) |
| Exposure time | : | 104 Weeks |

N-Methyl-2-pyrrolidone:

| | | |
|-------------------|---|---|
| Species | : | Rat, male |
| NOAEL | : | 169 mg/kg |
| LOAEL | : | 433 mg/kg |
| Application Route | : | Ingestion |
| Exposure time | : | 90 Days |
| Method | : | OECD Test Guideline 408 |
| Remarks | : | The test was conducted according to guideline |

| | | |
|-------------------|---|---|
| Species | : | Rat |
| NOAEL | : | 0.5 mg/l |
| LOAEL | : | 1 mg/l |
| Application Route | : | inhalation (dust/mist/fume) |
| Exposure time | : | 96 Days |
| Method | : | OECD Test Guideline 413 |
| Remarks | : | The test was conducted according to guideline |

| | | |
|-------------------|---|---|
| Species | : | Rabbit, male |
| NOAEL | : | 826 mg/kg |
| LOAEL | : | 1,653 mg/kg |
| Application Route | : | Skin contact |
| Exposure time | : | 20 Days |
| Method | : | OECD Test Guideline 410 |
| Remarks | : | The test was conducted equivalent or similar to guideline |

Fluazuron:

| | | |
|-------------------|---|---------------------------------|
| Species | : | Rat |
| LOAEL | : | 240 mg/kg |
| Application Route | : | Ingestion |
| Exposure time | : | 13 Weeks |
| Target Organs | : | Liver, Thyroid, Pituitary gland |

| | | |
|-------------------|---|--------------|
| Species | : | Rat |
| NOAEL | : | 10 mg/kg |
| LOAEL | : | 100 mg/kg |
| Application Route | : | Skin contact |
| Exposure time | : | 3 Weeks |

| | | |
|---------|---|-----|
| Species | : | Dog |
|---------|---|-----|

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Fluazuron / Abamectin Formulation

| | | | |
|----------------|------------------------------|-----------------------------|---|
| Version 9.1 | Revision Date: 14.04.2025 | SDS Number: 803734-00030 | Date of last issue: 24.03.2025 Date of first issue: 12.07.2016 |
|----------------|------------------------------|-----------------------------|---|

| | | |
|-------------------|---|-----------|
| NOAEL | : | 7.5 mg/kg |
| LOAEL | : | 110 mg/kg |
| Application Route | : | Ingestion |
| Exposure time | : | 52 Weeks |
| Target Organs | : | Liver |

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

| | | |
|-------------------|---|------------------------|
| Species | : | Rat |
| NOAEL | : | 1.5 mg/kg |
| Application Route | : | Oral |
| Exposure time | : | 24 Months |
| Target Organs | : | Central nervous system |
| Symptoms | : | Tremors, ataxia |

| | | |
|-------------------|---|------------------------|
| Species | : | Mouse |
| NOAEL | : | 4.0 mg/kg |
| Application Route | : | Oral |
| Exposure time | : | 24 Months |
| Target Organs | : | Central nervous system |
| Symptoms | : | Tremors, ataxia |

| | | |
|-------------------|---|------------------------|
| Species | : | Dog |
| NOAEL | : | 0.25 mg/kg |
| LOAEL | : | 0.5 mg/kg |
| Application Route | : | Oral |
| Exposure time | : | 53 Weeks |
| Target Organs | : | Central nervous system |
| Symptoms | : | Tremors, weight loss |
| Remarks | : | mortality observed |

| | | |
|-------------------|---|------------------------|
| Species | : | Monkey |
| NOAEL | : | 1.0 mg/kg |
| Application Route | : | Oral |
| Exposure time | : | 14 Weeks |
| Target Organs | : | Central nervous system |

7-Oxabicyclo[4.1.0]hept-3-ylmethyl 7-oxabicyclo[4.1.0]heptane-3-carboxylate:

| | | |
|-------------------|---|-------------------------|
| Species | : | Rat |
| NOAEL | : | 5 mg/kg |
| LOAEL | : | 50 mg/kg |
| Application Route | : | Ingestion |
| Exposure time | : | 90 Days |
| Method | : | OECD Test Guideline 408 |

2,6-Di-tert-butyl-p-cresol:

| | | |
|-------------------|---|-----------|
| Species | : | Rat |
| NOAEL | : | 25 mg/kg |
| Application Route | : | Ingestion |
| Exposure time | : | 22 Months |

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Fluazuron / Abamectin Formulation

| | | | |
|----------------|------------------------------|-----------------------------|---|
| Version 9.1 | Revision Date: 14.04.2025 | SDS Number: 803734-00030 | Date of last issue: 24.03.2025 Date of first issue: 12.07.2016 |
|----------------|------------------------------|-----------------------------|---|

Aspiration toxicity

Not classified based on available information.

11.2 Information on other hazards

Endocrine disrupting properties

Not classified based on available information.

Product:

Assessment : The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Experience with human exposure

Components:

N-Methyl-2-pyrrolidone:

Skin contact : Symptoms: Skin irritation

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Ingestion : Symptoms: May cause, Tremors, Diarrhoea, central nervous system effects, Salivation, tearing

SECTION 12: Ecological information

12.1 Toxicity

Components:

Propan-2-ol:

Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): 9,640 mg/l
Exposure time: 96 h

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): > 10,000 mg/l
Exposure time: 24 h

Toxicity to microorganisms : EC50 (Pseudomonas putida): > 1,050 mg/l
Exposure time: 16 h

N-Methyl-2-pyrrolidone:

Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): > 500 mg/l
Exposure time: 96 h

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): > 1,000 mg/l
Exposure time: 24 h
Method: DIN 38412
Remarks: The test was conducted according to guideline

Toxicity to algae/aquatic : ErC50 (Desmodesmus subspicatus (green algae)): 600.5 mg/l

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Fluazuron / Abamectin Formulation

| | | | |
|----------------|------------------------------|-----------------------------|---|
| Version 9.1 | Revision Date: 14.04.2025 | SDS Number: 803734-00030 | Date of last issue: 24.03.2025 Date of first issue: 12.07.2016 |
|----------------|------------------------------|-----------------------------|---|

| | |
|--|--|
| plants | Exposure time: 72 h EC10 (Desmodesmus subspicatus (green algae)): 92.6 mg/l Exposure time: 72 h |
| Toxicity to microorganisms | : EC50 (activated sludge): > 600 mg/l Exposure time: 30 min Method: ISO 8192 Remarks: The test was conducted according to guideline |
| Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) | : NOEC: 12.5 mg/l Exposure time: 21 d Species: Daphnia magna (Water flea) Method: OECD Test Guideline 211 Remarks: The test was conducted according to guideline |

Fluazuron:

| | |
|---|---|
| Toxicity to fish | : LC50 (Cyprinus carpio (Carp)): > 9.1 mg/l Exposure time: 96 h |
| Toxicity to daphnia and other aquatic invertebrates | : EC50 (Daphnia sp. (water flea)): 0.0006 mg/l Exposure time: 48 h |
| Toxicity to algae/aquatic plants | : NOEC (Raphidocelis subcapitata (freshwater green alga)): 27.9 mg/l Exposure time: 72 h |
| M-Factor (Acute aquatic toxicity) | : 1,000 |
| M-Factor (Chronic aquatic toxicity) | : 1,000 |

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

| | |
|---|--|
| Toxicity to fish | : LC50 (Oncorhynchus mykiss (rainbow trout)): 3.2 µg/l Exposure time: 96 h LC50 (Lepomis macrochirus (Bluegill sunfish)): 9.6 µg/l Exposure time: 96 h LC50 (Ictalurus punctatus (channel catfish)): 24 µg/l Exposure time: 96 h LC50 (Cyprinus carpio (Carp)): 42 µg/l Exposure time: 96 h LC50 (Cyprinodon variegatus (sheepshead minnow)): 15 µg/l Exposure time: 96 h |
| Toxicity to daphnia and other aquatic invertebrates | : EC50 (Americamysis): 0.022 µg/l Exposure time: 96 h EC50 (Daphnia magna (Water flea)): 0.34 µg/l |

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Fluazuron / Abamectin Formulation

Version
9.1

Revision Date:
14.04.2025

SDS Number:
803734-00030

Date of last issue: 24.03.2025
Date of first issue: 12.07.2016

Exposure time: 48 h

Toxicity to algae/aquatic plants : EC50 (Pseudokirchneriella subcapitata (green algae)): 100 mg/l
Exposure time: 72 h

M-Factor (Acute aquatic toxicity) : 10,000

Toxicity to microorganisms : EC50 : > 1,000 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition

Toxicity to fish (Chronic toxicity) : NOEC: 0.52 µg/l
Exposure time: 32 d
Species: Pimephales promelas (fathead minnow)

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC: 0.03 µg/l
Exposure time: 21 d
Species: Daphnia magna (Water flea)

NOEC: 0.0035 µg/l
Exposure time: 28 d
Species: Mysidopsis bahia (opossum shrimp)

M-Factor (Chronic aquatic toxicity) : 10,000

7-Oxabicyclo[4.1.0]hept-3-ylmethyl 7-oxabicyclo[4.1.0]heptane-3-carboxylate:

Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): 24 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 203

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): 40 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202

Toxicity to algae/aquatic plants : ErC50 (Raphidocelis subcapitata (freshwater green alga)): > 110 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

NOEC (Raphidocelis subcapitata (freshwater green alga)): 30 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

Toxicity to microorganisms : EC10 (activated sludge): 409 mg/l
Exposure time: 3 h
Method: OECD Test Guideline 209

2,6-Di-tert-butyl-p-cresol:

Toxicity to fish : LC50 (Danio rerio (zebra fish)): > 0.57 mg/l

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Fluazuron / Abamectin Formulation

Version
9.1

Revision Date:
14.04.2025

SDS Number:
803734-00030

Date of last issue: 24.03.2025
Date of first issue: 12.07.2016

| | |
|--|--|
| | Exposure time: 96 h Method: Directive 67/548/EEC, Annex V, C.1. |
| Toxicity to daphnia and other aquatic invertebrates | : EC50 (Daphnia magna (Water flea)): 0.48 mg/l Exposure time: 48 h Method: OECD Test Guideline 202 |
| Toxicity to algae/aquatic plants | : ErC50 (Pseudokirchneriella subcapitata (green algae)): > 0.24 mg/l Exposure time: 72 h Method: OECD Test Guideline 201 |
| | NOEC (Pseudokirchneriella subcapitata (green algae)): 0.24 mg/l Exposure time: 72 h Method: OECD Test Guideline 201 |
| M-Factor (Acute aquatic toxicity) | : 1 |
| Toxicity to microorganisms | : EC50 : > 10,000 mg/l Exposure time: 3 h Method: OECD Test Guideline 209 |
| Toxicity to fish (Chronic toxicity) | : NOEC: 0.053 mg/l Exposure time: 30 d Species: Oryzias latipes (Japanese medaka) Method: OECD Test Guideline 210 |
| Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) | : NOEC: 0.316 mg/l Exposure time: 21 d Species: Daphnia magna (Water flea) |
| M-Factor (Chronic aquatic toxicity) | : 1 |

12.2 Persistence and degradability

Components:

Propan-2-ol:

| | |
|------------------|--|
| Biodegradability | : Result: rapidly degradable |
| BOD/COD | : BOD: 1,19 (BOD5) COD: 2,23 BOD/COD: 53 % |

N-Methyl-2-pyrrolidone:

| | |
|------------------|---|
| Biodegradability | : Result: Readily biodegradable. Biodegradation: 73 % Exposure time: 28 d Method: OECD Test Guideline 301C Remarks: The test was conducted according to guideline |
|------------------|---|

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Fluazuron / Abamectin Formulation

Version
9.1

Revision Date:
14.04.2025

SDS Number:
803734-00030

Date of last issue: 24.03.2025
Date of first issue: 12.07.2016

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Stability in water : Hydrolysis: 50 %(< 12 h)

7-Oxabicyclo[4.1.0]hept-3-ylmethyl 7-oxabicyclo[4.1.0]heptane-3-carboxylate:

Biodegradability : Result: Not readily biodegradable.
Biodegradation: 71 %
Exposure time: 28 d
Method: OECD Test Guideline 301B

2,6-Di-tert-butyl-p-cresol:

Biodegradability : Result: Not readily biodegradable.
Biodegradation: 4.5 %
Exposure time: 28 d
Method: OECD Test Guideline 301C

12.3 Bioaccumulative potential

Components:

Propan-2-ol:

Partition coefficient: n-octanol/water : log Pow: 0.05

N-Methyl-2-pyrrolidone:

Partition coefficient: n-octanol/water : log Pow: -0.46
Method: OECD Test Guideline 107
Remarks: The test was conducted according to guideline

Fluazuron:

Partition coefficient: n-octanol/water : log Pow: 5.1

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Bioaccumulation : Bioconcentration factor (BCF): 52

Partition coefficient: n-octanol/water : log Pow: 4

7-Oxabicyclo[4.1.0]hept-3-ylmethyl 7-oxabicyclo[4.1.0]heptane-3-carboxylate:

Partition coefficient: n-octanol/water : log Pow: 1.34
Method: OECD Test Guideline 107

2,6-Di-tert-butyl-p-cresol:

Bioaccumulation : Species: Cyprinus carpio (Carp)
Bioconcentration factor (BCF): 330 - 1,800

Partition coefficient: n-octanol/water : log Pow: 5.1

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Fluazuron / Abamectin Formulation

| | | | |
|----------------|------------------------------|-----------------------------|---|
| Version 9.1 | Revision Date: 14.04.2025 | SDS Number: 803734-00030 | Date of last issue: 24.03.2025 Date of first issue: 12.07.2016 |
|----------------|------------------------------|-----------------------------|---|

12.4 Mobility in soil

Components:

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Distribution among environmental compartments : log Koc: > 3.6

12.5 Results of PBT and vPvB assessment

Product:

Assessment : This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

12.6 Endocrine disrupting properties

Product:

Assessment : The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

12.7 Other adverse effects

No data available

SECTION 13: Disposal considerations

13.1 Waste treatment methods

Product : Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities. Do not dispose of waste into sewer.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal. Empty containers retain residue and can be dangerous. Do not pressurize, cut, weld, braze, solder, drill, grind, or expose such containers to heat, flame, sparks, or other sources of ignition. They may explode and cause injury and/or death. If not otherwise specified: Dispose of as unused product.

SECTION 14: Transport information

14.1 UN number or ID number

ADN : UN 1993
ADR : UN 1993

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Fluazuron / Abamectin Formulation

| | | | |
|----------------|------------------------------|-----------------------------|---|
| Version 9.1 | Revision Date: 14.04.2025 | SDS Number: 803734-00030 | Date of last issue: 24.03.2025 Date of first issue: 12.07.2016 |
|----------------|------------------------------|-----------------------------|---|

RID : UN 1993

IMDG : UN 1993

IATA : UN 1993

14.2 UN proper shipping name

ADN : FLAMMABLE LIQUID, N.O.S.
(Propan-2-ol)

ADR : FLAMMABLE LIQUID, N.O.S.
(Propan-2-ol)

RID : FLAMMABLE LIQUID, N.O.S.
(Propan-2-ol)

IMDG : FLAMMABLE LIQUID, N.O.S.
(Propan-2-ol, Fluazuron, abamectin (combination of avermectin B1a and avermectin B1b) (ISO))

IATA : Flammable liquid, n.o.s.
(Propan-2-ol)

14.3 Transport hazard class(es)

| | Class | Subsidiary risks |
|-------------|-------|------------------|
| ADN | : 3 | |
| ADR | : 3 | |
| RID | : 3 | |
| IMDG | : 3 | |
| IATA | : 3 | |

14.4 Packing group

ADN
Packing group : III
Classification Code : F1
Hazard Identification Number : 30
Labels : 3

ADR
Packing group : III
Classification Code : F1
Hazard Identification Number : 30
Labels : 3
Tunnel restriction code : (D/E)

RID
Packing group : III
Classification Code : F1
Hazard Identification Number : 30
Labels : 3

IMDG

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Fluazuron / Abamectin Formulation

| | | | |
|----------------|------------------------------|-----------------------------|---|
| Version 9.1 | Revision Date: 14.04.2025 | SDS Number: 803734-00030 | Date of last issue: 24.03.2025 Date of first issue: 12.07.2016 |
|----------------|------------------------------|-----------------------------|---|

Packing group : III
Labels : 3
EmS Code : F-E, S-E

IATA (Cargo)

Packing instruction (cargo aircraft) : 366
Packing instruction (LQ) : Y344
Packing group : III
Labels : Flammable Liquids

IATA (Passenger)

Packing instruction (passenger aircraft) : 355
Packing instruction (LQ) : Y344
Packing group : III
Labels : Flammable Liquids

14.5 Environmental hazards

ADN

Environmentally hazardous : yes

ADR

Environmentally hazardous : yes

RID

Environmentally hazardous : yes

IMDG

Marine pollutant : yes

14.6 Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

14.7 Maritime transport in bulk according to IMO instruments

Remarks : Not applicable for product as supplied.

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles (Annex XVII) : Conditions of restriction for the following entries should be considered:
Number on list 3
Number on list 30: N-Methyl-2-pyrrolidone
Number on list 71: N-Methyl-2-pyrrolidone

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Fluazuron / Abamectin Formulation

Version
9.1

Revision Date:
14.04.2025

SDS Number:
803734-00030

Date of last issue: 24.03.2025
Date of first issue: 12.07.2016

Number on list 72: N-Methyl-2-pyrrolidone

Number on list 75: If you intend to use this product as tattoo ink, please contact your vendor.

Substance(s) or mixture(s) are listed here according to their appearance in the regulation, irrespective of their use/purpose or the conditions of the restriction. Please refer to the conditions in corresponding Regulation to determine whether an entry is applicable to the placing on the market or not.

| | | |
|---|---|--|
| REACH - Candidate List of Substances of Very High Concern for Authorisation (Article 59). | : | N-Methyl-2-pyrrolidone |
| Regulation (EU) No 2024/590 on substances that deplete the ozone layer | : | Not applicable |
| Regulation (EU) 2019/1021 on persistent organic pollutants (recast) | : | Not applicable |
| Regulation (EU) No 649/2012 of the European Parliament and the Council concerning the export and import of dangerous chemicals | : | abamectin (combination of avermectin B1a and avermectin B1b) (ISO) |
| REACH - List of substances subject to authorisation (Annex XIV) | : | Not applicable |
| Seveso III: Directive 2012/18/EU of the European Parliament and of the Council on the control of major-accident hazards involving dangerous substances. | | |

| | | Quantity 1 | Quantity 2 |
|-----|-----------------------|------------|------------|
| E1 | ENVIRONMENTAL HAZARDS | 100 t | 200 t |
| P5c | FLAMMABLE LIQUIDS | 5,000 t | 50,000 t |

Other regulations:

Take note of Directive 92/85/EEC regarding maternity protection or stricter national regulations, where applicable.

Take note of Directive 94/33/EC on the protection of young people at work or stricter national regulations, where applicable.

The components of this product are reported in the following inventories:

| | | |
|-------|---|----------------|
| AICS | : | not determined |
| DSL | : | not determined |
| IECSC | : | not determined |

15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Fluazuron / Abamectin Formulation

Version
9.1

Revision Date:
14.04.2025

SDS Number:
803734-00030

Date of last issue: 24.03.2025
Date of first issue: 12.07.2016

SECTION 16: Other information

Other information : Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Full text of H-Statements

H225 : Highly flammable liquid and vapour.
H300 : Fatal if swallowed.
H311 : Toxic in contact with skin.
H315 : Causes skin irritation.
H317 : May cause an allergic skin reaction.
H319 : Causes serious eye irritation.
H330 : Fatal if inhaled.
H335 : May cause respiratory irritation.
H336 : May cause drowsiness or dizziness.
H341 : Suspected of causing genetic defects.
H360D : May damage the unborn child.
H361fd : Suspected of damaging fertility. Suspected of damaging the unborn child.
H372 : Causes damage to organs through prolonged or repeated exposure if swallowed.
H373 : May cause damage to organs through prolonged or repeated exposure.
H400 : Very toxic to aquatic life.
H410 : Very toxic to aquatic life with long lasting effects.
H412 : Harmful to aquatic life with long lasting effects.

Full text of other abbreviations

Acute Tox. : Acute toxicity
Aquatic Acute : Short-term (acute) aquatic hazard
Aquatic Chronic : Long-term (chronic) aquatic hazard
Eye Irrit. : Eye irritation
Flam. Liq. : Flammable liquids
Muta. : Germ cell mutagenicity
Repr. : Reproductive toxicity
Skin Irrit. : Skin irritation
Skin Sens. : Skin sensitisation
STOT RE : Specific target organ toxicity - repeated exposure
STOT SE : Specific target organ toxicity - single exposure
2004/37/EC : Europe. Directive 2004/37/EC on the protection of workers from the risks related to exposure to carcinogens, mutagens or reprotoxic substances at work - Annex III
2009/161/EU : Europe. COMMISSION DIRECTIVE 2009/161/EU establishing a third list of indicative occupational exposure limit values in implementation of Council Directive 98/24/EC and amending Commission Directive 2000/39/EC
IE OEL : Ireland. List of Chemical Agents and Carcinogens with Occupational Exposure Limit Values - Code of Practice, Schedule 1 and 2
2004/37/EC / STEL : Short term exposure limit
2004/37/EC / TWA : Long term exposure limit

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Fluazuron / Abamectin Formulation

| | | | |
|----------------|------------------------------|-----------------------------|---|
| Version 9.1 | Revision Date: 14.04.2025 | SDS Number: 803734-00030 | Date of last issue: 24.03.2025 Date of first issue: 12.07.2016 |
|----------------|------------------------------|-----------------------------|---|

| | |
|-------------------------------|--|
| 2009/161/EU / TWA | : Limit Value - eight hours |
| 2009/161/EU / STEL | : Short term exposure limit |
| IE OEL / OELV - 8 hrs (TWA) | : Occupational exposure limit value (8-hour reference period) |
| IE OEL / OELV - 15 min (STEL) | : Occupational exposure limit value (15-minute reference period) |

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of Very High Concern; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TRGS - Technical Rule for Hazardous Substances; TSCA - Toxic Substances Control Act (United States); UN - United Nations; vPvB - Very Persistent and Very Bioaccumulative

Further information

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Classification of the mixture:

| | |
|---------------|------|
| Flam. Liq. 3 | H226 |
| Acute Tox. 4 | H332 |
| Skin Irrit. 2 | H315 |
| Eye Irrit. 2 | H319 |
| Skin Sens. 1 | H317 |

Classification procedure:

| |
|-------------------------------------|
| Based on product data or assessment |
| Calculation method |
| Calculation method |
| Calculation method |
| Calculation method |

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Fluazuron / Abamectin Formulation

| | | | |
|----------------|------------------------------|-----------------------------|---|
| Version 9.1 | Revision Date: 14.04.2025 | SDS Number: 803734-00030 | Date of last issue: 24.03.2025 Date of first issue: 12.07.2016 |
|----------------|------------------------------|-----------------------------|---|

| | | |
|-------------------|-------|--------------------|
| Muta. 2 | H341 | Calculation method |
| Repr. 1B | H360D | Calculation method |
| STOT SE 3 | H335 | Calculation method |
| STOT SE 3 | H336 | Calculation method |
| STOT RE 2 | H373 | Calculation method |
| Aquatic Acute 1 | H400 | Calculation method |
| Aquatic Chronic 1 | H410 | Calculation method |

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

IE / EN